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Optimization approaches to dispensary observation of 
patients with polymorbid pathology on the metabolic 
syndrome background
Valeria N. Thorikova*, Andrej L. Yarosh, Aleksandr A. Karpachev, Sergei N. Gontarev
INTRODUCTION
Non-communicable diseases pose a serious social and 
economic problem threat of a global scale, in their 
structure, the leading positions for causes of death 
are cardiovascular diseases and diabetes mellitus.
[1] Metabolic syndrome, being widespread in the 
world and, particularly, in the Russian Federation 
increases the risk of their development[2] and is also 
a background condition for the development of 
polymorbid pathology.[3,4] Patients with non-infectious 
diseases often have polymorbid pathology and are 
subject to a regular medical checkup in outpatient 
medical organizations, where an overwhelming part 
of the doctor’s time is spent on work with them.[5] For 
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implementing dispensary observation (DO) of high 
quality, the structure and the assessment of existing 
concomitant diseases (polymorbid pathology) should 
be taken into account. At present, the generally 
accepted terminology of concepts and structures as 
well as a single method for the quantitative evaluation 
of polymorbidity is absent.[6] Among the existing 
methods for quantifying polymorbidity, the most 
common are systems CIRS and adjusted clinical 
groups, indices Kaplan-Feinstein, Charlson, index 
of coexistent disease, geriatric index of comorbidity, 
functional comorbidity index, total illness burden 
index, duke severity of illness scale, and scale 
care dependency scale. Their comparative reviews 
presented in papers of de Groot et al.,[7] Fortin et al.,[8] 
Zekry et al.,[9] and Huntley et al.[10] unite the conclusion 
about their narrow specialization and the need to 
develop a universal tool for assessing polymorbidity. 
Another promising direction for researchers is seen 
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in the personification and activation of medical 
checkup, which can be achieved by upgrading the 
medical checkup program.[11] Being developed by P.A. 
Sheptun together with coauthors,[12] the innovative 
program of DO (IPDO), which focuses on lifestyle 
modification and a personified approach, using the 
therapeutic and prophylactic potential of the patient’s 
microsocial environment, has shown effectiveness 
in the implementation of patients medical checkup 
with MS.
Objective
The purpose of the paper is to develop new approaches 
to the implementation of dispensary observation (DO) 
of patients with polymorbid pathology against the 
background of the metabolic syndrome (MS) and 
evaluate their efficiency.
MATERIALS AND TECHNIQUES
The method of polymorbidity complex evaluation 
(MPCE) was used. The main direction of the research 
was related to the development and validation 
of the automated MPCE. Its essence consisted 
of the simultaneous registration of anamnestic, 
clinical, laboratory, instrumental, functional, and 
psychological parameters of the patient’s health 
(indicators), for convenience they were clustered 
[Table 1].
Clinical information about the patient’s health by 
means of a scaling procedure was transformed 
according to the quantitative or qualitative values of 
the indicators into points in the range from 0 to 10. 
Separate formulas for each cluster were developed, 
with the help of which intermediate health indices were 
counted, expressed in c.u.: The index of unmodified 
health meter (I1) (Formule 1), modifiable health 
meter (I2) (Formule 2), comorbidity pathology (I3) 
(Formule 3), multimorbidity pathology (I4) (Formule 
4), and functional index (I5) (Formule 5).
I1 =
100
 (1)
I2 =
20 3.
 (2)
I3 =
31
 (3)
I = 624  (4)
I = 20.55  (5)
Table 1: The name of indicators and clusters of the 
MPCE
Name of indicators and clusters Indicator code
1 2
Cluster 1: Unmodified risk factors for 
non-communicable diseases
Age 1.1
Gender 1.2
The age of menopause (for women) 1.3
Family history of early CVD and 
oncological diseases
1.4
Cluster 2: Modifiable risk factors for 
non-communicable diseases
Nicotine addiction 2.5
Eating patterns 2.6
Body weight index 2.7
Waist measurement 2.8
Level of systolic blood pressure 2.9
Level of pulse blood pressure 2.10
Ankle–brachial index 2.11
Frequency of respiratory movements 2.12
Heart rate 2.13
Total cholesterol 2.14
Low-density lipoprotein cholesterol 2.15
High-density lipoprotein cholesterol 2.16
Triglycerides 2.17
Fasting glycemia 2.18
PPG 2.19
Glycosylated hemoglobin 2.20
Urinary excretion of albumin 2.21
Proteinuria 2.22
Hypertrophy of myocardium of the 
left ventricle
2.23
Ultrasonic signs of thickening of the 
artery wall or atherosclerotic plaques 
of the main vessels
2.24
Cluster 3: Comorbid metabolic 
syndrome pathology (cardiovascular 
syndromes and nosology)
Hypertensive disease stage 3.25
Cardiac infarction 3.26
Exertional angina 3.27
Heart rhythm disorder 3.28
Artificial pacemaker, coronary 
revascularization
3.29
Stage of chronic heart failure 3.30
Diabetes mellitus 3.31
Clinically significant lesion of 
peripheral arteries
3.32
Acute cerebrovascular accident or 
transient ischemic attack
3.33
Chronic kidney disease 3.34
Cluster 4: Multimorbid metabolic 
syndrome pathology (other nosologies)
Malignant neoplasms 4.35
Non-coronary diseases of the 
circulatory system
4.36
Diseases of peripheral vessels 4.37
Mental and behavioral disorders 4.38
Diseases of the nervous system 4.39
Diseases of the eye and its adnexa 4.40
Diseases of the ear and mastoid 
process
4.41
Diseases of the respiratory system 4.42
Diseases of the digestive system 4.43
Diseases of the skin and 
subcutaneous tissue
4.44
Diseases of the musculoskeletal and 
connective tissue
4.45
(Contd...)
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Where, i - summation index and x - indicator value, 
point.
Intermediate indices for each cluster took values in the 
range of 0–1.0 c.u. The value 1.0 c.u. corresponded to 
the absence of a pathological effect on the patient’s 
health indicators of this cluster, and c.u - the greatest 
possible pathological effect. Integrative result 
MPCE is calculated by the formula (formula 6) and 
was called the index of polymorbidity (IP), being 
expressed in c.u.
IP=100  (6)
Where, i - summation index and x - indicator value, 
point.
IP took values in the range from 0 to 1.0 c.u. The value 0 
c.u corresponded to polymorbidity, incompatible with 
life and 1.0 c.u - its absence. The level stratification 
of polymorbidity was developed with the purpose of 
its qualitative assessment, as well as for the formation 
of prognostic recommendations in the provision of 
outpatient medical care [Table 2].
For automation of MPCE, the program “Evaluation 
of patient’s polymorbidity” was developed with 
the usage software language С++. After entering 
information about the patient’s health in its fields, the 
user is provided with both qualitative and structural 
evaluation of the patient’s polymorbidity, specific 
prognostic recommendations routinely performed in 
outpatient work in the medical checkup process.
Sensitivity, reliability, and validity of MPCE were 
reliably established.
MPCE was introduced in medical outpatient clinics 
in the Belgorod region. In the process of business 
processes mapping, a comparative motion-time 
measurement was used that was spent by the district 
doctor on the dispensary reception of the patient using 
the MPCE and without its application. Measurements 
of the time spent by 10 doctors of the polyclinic 
No. 7 “City Hospital No. 2 in Belgorod” (CH2) were 
carried out.
The second direction of the study was related to the 
evaluation of the effectiveness of IPDO in patients 
with polymorbid pathology on the background of MS. 
110 patients of polyclinic No. 7 CH2 - 47 men (42.7%) 
and 63 women (57.3%) with polymorbid pathology, 
IIIa group of health status according to the results of 
clinical examination and MS.
All patients that were included into the examining 
were treated by DO for 6 months. The choice of the 
DO program was carried out randomly by dividing 
the patients into two groups, for this purpose, simple 
randomization was done by the random number 
method. Patients of the 1st group (n = 61) underwent 
DO according to the traditional DO program (TPDO). 
Patients from the 2nd group (n = 49) were treated 
according to the author’s program - IPDO.
Patients were examined according to the classical 
conventional method. Laboratory (blood and clinical, 
biochemical, clinical urine, daily urinary albumin 
excretion, glomerular filtration rate according to 
the formula CKD-EPI, and modification of 2011) 
and instrumental methods (ECG, echocardiography, 
ultrasound of brachiocephalic arteries, oxygen 
Name of indicators and clusters Indicator code
Diseases of the blood 4.46
Other diseases of the endocrine 
system
4.47
Diseases of the genitourinary system 4.48
Cluster 5: Functional status
Functional class of chronic heart 
failure
5.49
Respiratory failure 5.50
Dysfunction of the joints 5.51
The degree of violation of the 
statodynamic function
5.52
Hepatic encephalopathy 5.53
Tolerance to physical activity 5.54
Degree of anxiety and depression 5.55
MPCE: Method of polymorbidity complex evaluation, DO: Dispensary 
observation CVD: Cardiovascular disease
Table 1: (Continued) Table 2: Value stratification of the polymorbidity 
index
Stratification purpose Stratification
Quantification 
polymorbidity
1.0–0.80 c.u. low level
0.79–0.50 c.u - middle level
0.49–0 c.u high level
Determination of the 
cardiovascular risk 
degree in planned 
surgical interventions
1.0-0.80 c.u. - risk of low 
degree,
0.79–0.50 c.u. - middle,
0.49–0.30 c.u. - high ≤0.29 
c.u - extremely high degree
Spa treatment 1.0–0.70 c.u in any types 
of sanatorium-and-spa 
organizations;
0.69–0.40 c.u - only in local 
cardiological sanatoria
0.40–0 c.u. - contraindicated.
Express analysis of 
permanent incapacity for 
work
≤0.60 c.u presence of 
incapacity for work.
Prediction of the course 
and outcome of the 
disease
1.0–0.60 c.u. - favorable 
prognosis
0.59–0.30 c.u - suspicious
0.29–0.20 c.u. - unfavorable
0.19–0.10 c.u - very bad
0.10–0.0 c.u. - a direct 
indication of the lethal 
outcome inevitability
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saturation, daily monitoring of ECG and blood 
pressure, and a test with dosed physical activity) 
were used. Additional methods of investigation 
were Fagherstrom test, hospital scale of anxiety and 
depression, and assessment of nutritional rationality.
RESULTS
Clinical characteristics of patients
There were 47 men (42.7%) and 63 women (57.3%) of 
the 110 patients. The average number of nosological 
forms was 4.5 (3.2–5.1). The comorbid MS pathology 
prevailed: Hypertension (98.2%, 108/110), in more 
than half of cases (60%, 66/110) complicated by the 
presence associated clinical conditions, and in a third 
of cases - diabetes mellitus (27.3% 30/110). The most 
common are respiratory diseases (69.1%, 76/110), 
digestion (63.6%, 70/110), and musculoskeletal and 
connective tissue (69.1%, 76/110) prevailing among 
the multimorbid MS nosological forms.
IPDO for 6 months additionally allowed reducing the 
number of patients with nicotine dependence, violation 
of the statodynamic function, anxiety and depression, 
reducing median waist volume, body mass index, 
systolic blood pressure, carbohydrate metabolism, 
reducing the number and severity of ear and mastoid 
diseases, and organs respiration [Table 3].
Index medians Kaplan-Feinstein, Charlson, and 
the number of points in the system CIRS, I1 and 
I3 МКОP statistically did not change their values 
significantly [Table 4].
Statistically significant increase in medians I4 и I5 
MPCE was registered regardless of the DO program, 
IP and I2 in the group IPDO. In the group IPDO the 
number of patients with “high” (from 10.2%, 5/49 
to 4.1%, 2/49) and “average” (from 75.5%, 37/49 
to 57.1%, 28/49) and level of polymorbidity has 
decreased but “low” (from 14.3%, 7/49 to 38.8%, 
19/49) level has increased.
In the IPDO group, statistically significant fewer 
cases of exacerbations of chronic diseases, the 
number of calls for emergency medical services and 
hospitalizations, and the number of days of disability 
in comparison with the TPDN group were recorded 
for the 6 months of the observation [Table 5].
Comparative timing of the doctor’s time spent on 
dispensary:  With the use of MPCE, the median time 
of dispensary admission of a patient with polymorbid 
pathology against the background of MS was 
12.5 (10.4–14.8) min and without the use of MPCE 
by the same doctors - 17.6 (13.9–20.8) min (P = 
0.0432/0.0587).
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Table 5: Indicators of the effectiveness of 6 months DO in accordance with the chosen program.
Indicators of the DO 
effectiveness
Group of traditional 
DO program n=56 (%)
Group of innovative 
DO program n=49 (%)
Significance point P Chi‑square 
method of McNemar
Number of cases of temporary 
incapacity for work
5 (8.9) 3 (6.1) 0.0875
Number of days of temporary 
incapacity for work
39 18 0.0146
Number of hospitalizations, 
including emergency medical 
indications, for exacerbations 
and complications of diseases
8 (14.3) 4 (8.2) 0.0118
Number of cases of 
exacerbations of chronic 
diseases that did not require 
hospitalization
12 (21.4) 7 (14.3) 0.0204
Number of emergency calls 10 (17.9) 5 (10.2) 0.0143
Number of deceased 0 0 ‑
DISCUSSION
MS is a widespread background condition for the 
polymorbid pathology development and non-infectious 
diseases requiring DO. A contingent of an outpatient 
clinic with a polymorbid pathology against the 
background of MS was studied and is subject to DO: 
These are patients who, on average, have more than four 
concurrent nosological forms including hypertensive 
disease, in more than half of cases, it is complicated by 
the presence of associated clinical conditions.
The study proved the effectiveness of new approaches 
to the implementation of DO of these patients 
consisting in the expansion of the DO program 
and the use of the method of the comprehensive 
evaluation of polymorbidity (MPCE) as its tool. 
DO of patients with PPMS requires control over 
the course of several concurrent nosological forms 
and related functional disorders, taking into account 
existing and preventing the development of new 
target organ lesions and working with risk factors that 
affect the prognosis, as well as early recognition of 
persistent disability, evaluation of the sanatorium-spa 
treatment possibility, cardiovascular risk under the 
condition of planned surgical interventions. Using 
the MPCE as a DO tool effectively solves these 
problems by providing the clinician with structured 
information about the patient’s health status. The 
computer program “Evaluation of the patient’s 
polymorbidity” accelerates and simplifies this 
process by automating the actions and the possibility 
of creating and storing a database of patients in DO. 
The expansion of the DO program, which focuses on 
lifestyle modification, the personified approach, and 
the use of the therapeutic and prophylactic potential 
of the patient’s microsocial environment, has shown 
efficacy in the implementation of DO patients with 
polymorbid pathology in the background of MS and 
an advantage over TDOP.
The use of new approaches in the implementation 
of DO patients with polymorbid pathology on the 
background of MS allows optimizing and improving 
its implementation in medical organizations that 
provide assistance in outpatient settings.
CONCLUSION
1. It is necessary to implement the MPCE, automated 
by the computer program “Evaluation of the 
patient’s polymorbidity,” as a tool for evaluating 
polymorbidity. In ambulatory polyclinic medical 
organizations for DO of patients with polymorbid 
pathology on the background of MS.
2. It is necessary to organize innovative schools on 
the basis of outpatient and polyclinic medical 
organizations with a group of teachers who 
underwent preliminary training in the “Andragogic 
principles of patient education” program to 
implement an innovative outpatient program 
focusing on lifestyle modification and a personified 
approach using the therapeutic and prophylactic 
potential microsocial environment of the patient.
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